Rx00004 - Adalimumab


Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00004
Primary Indication
Secondary Indication

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
Plaque Psoriasis severe chronic plaque psoriasis 6551 6551 6551 615.925 0 0.0
severe chronic plaque psoriasis Plaque Psoriasis 6551 6551 6551 615.925 0 0.0
adult moderate chronic plaque psoriasis Plaque Psoriasis 6551 6551 6551 615.925 0 0.0
Crohn's Disease pediatric Crohn's disease 11834 11834 11834 340.96 0 0.0
Psoriatic Arthritis Plaque Psoriasis 516 1275 6551 249.268 0 0.0
Rheumatoid Arthritis severely active polyarticular juvenile idiopathic arthritis 107 7378 352 166.241 8.05E-187 2.58e-183
Ankylosing Spondylitis Rheumatoid Arthritis 61 496 7378 67.258 9.34E-86 3e-82

Shared Genetic Architectures of Disease Pairs

Click row to show all

Disease A Disease B Adjusted P-Value Shared Gene IDs
ANKYLOSING SPONDYLITIS RHEUMATOID ARTHRITIS 4.6e-100 3807, ABCF1, ACE, ADA, ADRB1, ALPL, ANKH, ANO6, ANTXR2, AR, ASPN, ATG16L1, BMP8A, BTNL2, C11orf30, C1orf106, C1orf81, C4A, C4B, C6orf47, CARD8, CARD9, CCL2, CCL7, CCR6, CD14, CD274, CDKAL1, CNOT3, CNTN5, COL6A1, CTLA4, CYP1A1, CYP2D6, DBP, EDIL3, EEF1DP3, ERAP1, ERAP2, FCGR2B, FCRL3, FCRL4, FCRL5, FOXO1, GC, GCKR, GNL1, GPSM3, GSDMB, HAPLN1, HAVCR2, HHAT, HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB4, HLA-E, HSPA1A, HSPA2, ICOSLG, IKZF3, IL10, IL12B, IL17RA, IL18R1, IL18RAP, IL19, IL1A, IL1B, IL1F10, IL1R1, IL1R2, IL1RN, IL23R, IL2RA, IL33, IL36A, IL36B, IL36G, IL36RN, IL37, IL4, IL6, IL6R, IRGM, ITLN1, JAK2, JMY, KDM5A, KIF21B, KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DP1, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1, KIR3DL2, KIR3DL3, KIR3DP1, KIR3DS1, LAIR2, LRP5, LRRK2, LTA, LTBR, LYRM4, MBL2, MEFV, MICA, MICA, MIR182, MIR196A2, MIR27A, MMP2, MMP3, MSH5, MST1, MSX2, MTHFR, MUC19, NELL1, NFKB1, NFKBIA, NKX2-3, NLRP1, NLRP3, NOD2, NOS3, ORAI1, ORMDL3, PADI4, PBMUCL1, PDCD1, PDCD1LG2, PPARGC1B, PRKRA, PRR3, PSMB8, PSMB9, PSMD7, PSTPIP1, PTGER4, PTPN2, PTPN22, PUS10, RGS6, RUNX3, SCNN1A, SERPINA1, SLC22A23, SNAPC4, SOD2, STAT3, STAT4, TAP1, TAP2, TBKBP1, TGFB1, TIMP1, TLR2, TLR4, TLR8, TLR9, TNAP, TNF, TNFRSF11A, TNFRSF11B, TNFRSF1A, TNFRSF1B, TNFSF11, TNFSF15, TRADD, TRAF5, TRIM31, TSHR, TXNDC5, UGT2B17, VDR, VEGFA, VIPR1, ZNF365, ZPBP2
PSORIATIC ARTHRITIS RHEUMATOID ARTHRITIS 4.24e-83 3807, ABCF1, ABCG2, ABHD16A, ACE, AFF3, AGER, AGPAT1, AIF1, ATAT1, ATF6B, ATP6V1G2, BAG6, BAK1, BRD2, BTNL2, C2, C6orf10, C6orf125, C6orf15, C6orf26, C6orf27, C6orf47, C6orf48, CCHCR1, CCL21, CCR2, CCR5, CD28, CDSN, CFB, CLIC1, COL11A2, CSNK2B, CTLA4, CYP1A1, CYP2C19, DAXX, DDR1, DDX39B, DHFR, DHX16, DOM3Z, DPCR1, EGFL8, EHMT2, ERAP1, FCGR2A, FCGR3A, FKBPL, FLJ16341, GNL1, GPANK1, GPSM3, HFE, HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-E, HLA-G, HSD17B8, HSPA1A, HSPA1L, IFNG, IL10, IL12A, IL12B, IL12RB1, IL13, IL17A, IL17RA, IL1A, IL1B, IL1R1, IL1RN, IL2, IL23A, IL23R, IL36A, IL36RN, IL37, IL4, IL4R, IL6, IL8, IP6K3, IRAK1, ITPR3, KIF5A, KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DP1, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1, KIR3DL2, KIR3DL3, KIR3DP1, KIR3DS1, LCE3B, LCE3C, LEMD2, LST1, LTA, LY6G5B, LY6G5C, LY6G6C, LY6G6F, MCCD1, MDC1, MDM2, MEFV, MICA, MICA, MICB, MIR146A, MLN, MOG, MSH5, MTHFR, NFKB1, NFKBIA, NFKBIL1, NLRP3, NOD2, NONOP2, NOS2, NOTCH4, NRM, OR2H1, OR2H2, PBX2, POU5F1, PPARG, PPP1R11, PPT2, PRR3, PRRC2A, PRRT1, PSMA6, PSMB8, PSMB9, PSORS1C1, PSORS1C2, PSTPIP1, PTPN22, PTTG1, RDBP, REL, RFC1, RNF5, RUNX1, SFTA2, SKIV2L, SLC22A4, SLC22A5, SLC44A4, SOD2, STAT3, STAT4, STK19, SYNGAP1, TAP1, TAP2, TAPBP, TNF, TNFAIP3, TNFRSF10A, TNFRSF11A, TNFRSF11B, TNFRSF1A, TNFRSF1B, TNFSF11, TNFSF15, TNIP1, TNXB, TP53, TRIM10, TRIM15, TRIM26, TRIM31, TRIM40, VARS, VARS2, VDR, VEGFA, VPS52, ZBTB12, ZBTB22, ZNF311

Chemical, Pharmacological and Biological Annotations


ATC Code:
L04AB04
Brand:
Humira Pen (Abbott Laboratories)
Categories:
Antirheumatic Agents; Anti-Inflammatory Agents; Immunosuppressive Agents
Classification:
Kingdom:
Organic Compounds
Superclass:
Organic Acids
Class:
Carboxylic Acids and Derivatives
Subclass:
Amino Acids, Peptides, and Analogues
Indication:
For treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.
Pharmacodynamics:
Used in the treatment of immune system mediated diseases, adalimumab binds specifically to TNF-alpha and blocks its general cytokine effects, thereby reducing TNF-induced inflammation and halting tissue destruction.
Description:
Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.
Mechanism:
Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement.

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Not Available from DrugBank


Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org